• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

    2/8/22 4:28:51 PM ET
    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRXT alert in real time by email
    SC 13G/A 1 bluwu_13ga.htm BLUWU 13G/A

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
    Clarus Therapeutics Holdings, Inc.

    (formerly known as Blue Water Acquisition Corporation)

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    18271L107

    (CUSIP Number)
     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Hudson Bay Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Sander Gerber

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     
     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Clarus Therapeutics Holdings, Inc. (formerly known as Blue Water Acquisition Corporation), a Delaware corporation (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 555 Skokie Boulevard, Suite 340, Northbrook, Illinois 60062.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by Hudson Bay Capital Management LP (the "Investment Manager") and Mr. Sander Gerber ("Mr. Gerber"), who are collectively referred to herein as "Reporting Persons."

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 28 Havemeyer Place, 2nd Floor, Greenwich, Connecticut 06830.

     

    Item 2(c). CITIZENSHIP:
       
      The Investment Manager is a Delaware limited partnership.  Mr. Gerber is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      18271L107

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ý Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

     
     

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The Investment Manager serves as the investment manager to HB Strategies LLC, in whose name the securities reported herein were held.  As such, the Investment Manager may have been deemed to be the beneficial owner of all securities held by HB Strategies LLC.  Mr. Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of the Investment Manager.  Mr. Gerber disclaims beneficial ownership of these securities.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.
     
     

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: February 8, 2022

     

    HUDSON BAY CAPITAL MANAGEMENT LP    
         
         
    By: /s/ Sander Gerber    
    Name: Sander Gerber    
    Title: Authorized Signatory    
         
         
    /s/ Sander Gerber    
    SANDER GERBER    

     

    Get the next $CRXT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRXT

    DatePrice TargetRatingAnalyst
    10/13/2021$10.00Buy
    Truist Securities
    10/6/2021$12.00Buy
    Needham
    9/29/2021$13.00Buy
    Maxim Group
    More analyst ratings

    $CRXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Prygocki Mark A Sr was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:06:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Murphy Kimberly M was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:04:31 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Amory John Kenneth was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:02:52 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    SEC Filings

    See more
    • SEC Form 15-12G filed by Clarus Therapeutics Holdings Inc.

      15-12G - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:35:06 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events

      8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:26:43 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clarus Therapeutics Holdings Inc.

      S-8 POS - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:22:23 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist Securities initiated coverage on Clarus Therapeutics Hldgs with a new price target

      Truist Securities initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $10.00

      10/13/21 7:15:13 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Clarus Therapeutics Hldgs with a new price target

      Needham initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $12.00

      10/6/21 6:00:16 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Clarus Therapeutics with a new price target

      Maxim Group initiated coverage of Clarus Therapeutics with a rating of Buy and set a new price target of $13.00

      9/29/21 8:32:42 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder

      Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets). The bidding and auction procedures were approved by the U. S. Ba

      10/18/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

      NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testos

      9/5/22 10:19:04 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

      Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcount; transition of Chief Financial Officer role NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies, today reported financial results for the second quarter of 2022. Clarus also announced that it is pursuing an immediate reduction in staff as i

      8/18/22 4:05:07 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Leadership Updates

    Live Leadership Updates

    See more
    • Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

      Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat

      6/23/22 4:30:00 PM ET
      $BWV
      $CRXT
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

      Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova has nearly 30 years of experience in the pharmaceutical and biotech industries. She most recently led clinical development programs

      1/18/22 9:05:00 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      2/14/23 12:29:21 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      7/6/22 4:00:10 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      4/21/22 8:43:02 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Financials

    Live finance-specific insights

    See more
    • Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

      NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be

      5/12/22 9:05:00 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

      2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO® increased 11% sequentially and increased 81% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., March 30, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the fourth quarter and full year of 2021. "Clarus delivered solid growth in net revenu

      3/30/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

      NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes. Clarus will host a conference call on Wednesday, March 30, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 5454819. A live webcast and replay of the

      3/29/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care